BBHC
ITCI

Brown Brothers Harriman & Co’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Brown Brothers Harriman & Co’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7
Closed -$585 – 1518
2024
Q4 		$585 Buy
+7
New +$575 ﹤0.01% 1399

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Brown Brothers Harriman & Co's ITCI Position: Q1 2025 in Review

Brown Brothers Harriman & Co sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 7 shares — an estimated $585 sold.

Brown Brothers Harriman & Co first reported a position in ITCI in Q4 2024 and held it in 1 quarter. The position peaked at $585 in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Brown Brothers Harriman & Co reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 7 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $585.
  • Brown Brothers Harriman & Co first reported a position in Intra-Cellular Therapies Inc. in Q4 2024 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Intra-Cellular Therapies Inc. position peaked at $585 in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2025, filed 14 May 2025.